Trial Outcomes & Findings for Reward-based Technology to Improve OUD Treatment (NCT NCT05180669)
NCT ID: NCT05180669
Last Updated: 2026-02-06
Results Overview
Percentage of patients who schedule an outpatient Suboxone intake prior to discharge from acute care
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
41 participants
Primary outcome timeframe
1 timepoint - Before patients are discharged from acute care at the time of study enrollment
Results posted on
2026-02-06
Participant Flow
Individuals with OUD presenting to an acute care setting were approached to participate in the study between August 2022 and September 2024. Those who met the eligibility criteria and confirmed their interest in participating in the study were enrolled. The first participant was enrolled November 18, 2022 and the last patient was enrolled July 9, 2024.
Of the 3,006 individuals with OUD who were approached, 84 were eligible and 41 agreed to participate in the study. These 41 participants were then randomized to OARSCM (21 participants) or TAU MyMAT (20 participants).
Participant milestones
| Measure |
OARSCM
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Overall Study
3-month Follow-up
|
1
|
0
|
|
Overall Study
NOT COMPLETED
|
21
|
20
|
|
Overall Study
6-month Follow-up
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
STARTED
|
21
|
20
|
|
Overall Study
1-month Follow-up
|
2
|
0
|
Reasons for withdrawal
| Measure |
OARSCM
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
21
|
20
|
Baseline Characteristics
Reward-based Technology to Improve OUD Treatment
Baseline characteristics by cohort
| Measure |
OARSCM
n=21 Participants
OARSCM (n = 51) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
n=20 Participants
TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
Total
n=41 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=192 Participants
|
0 Participants
n=170 Participants
|
0 Participants
n=185 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
21 Participants
n=192 Participants
|
19 Participants
n=170 Participants
|
40 Participants
n=185 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=192 Participants
|
1 Participants
n=170 Participants
|
1 Participants
n=185 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=192 Participants
|
8 Participants
n=170 Participants
|
16 Participants
n=185 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=192 Participants
|
12 Participants
n=170 Participants
|
25 Participants
n=185 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
7 Participants
n=192 Participants
|
5 Participants
n=170 Participants
|
12 Participants
n=185 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
14 Participants
n=192 Participants
|
15 Participants
n=170 Participants
|
29 Participants
n=185 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=192 Participants
|
0 Participants
n=170 Participants
|
0 Participants
n=185 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=192 Participants
|
0 Participants
n=170 Participants
|
0 Participants
n=185 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=192 Participants
|
0 Participants
n=170 Participants
|
0 Participants
n=185 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=192 Participants
|
0 Participants
n=170 Participants
|
0 Participants
n=185 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=192 Participants
|
1 Participants
n=170 Participants
|
2 Participants
n=185 Participants
|
|
Race (NIH/OMB)
White
|
15 Participants
n=192 Participants
|
12 Participants
n=170 Participants
|
27 Participants
n=185 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=192 Participants
|
2 Participants
n=170 Participants
|
3 Participants
n=185 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=192 Participants
|
5 Participants
n=170 Participants
|
9 Participants
n=185 Participants
|
PRIMARY outcome
Timeframe: 1 timepoint - Before patients are discharged from acute care at the time of study enrollmentPopulation: All enrolled participants were included.
Percentage of patients who schedule an outpatient Suboxone intake prior to discharge from acute care
Outcome measures
| Measure |
OARSCM
n=21 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
n=20 Participants
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Percent Outpatient Intake Scheduled - Phase 2 RCT
Yes
|
12 Participants
|
8 Participants
|
|
Percent Outpatient Intake Scheduled - Phase 2 RCT
No
|
9 Participants
|
12 Participants
|
PRIMARY outcome
Timeframe: Typically, within ~48 hours of discharge from acute carePopulation: All enrolled participants were included.
Percentage of patients who complete their outpatient Suboxone intake
Outcome measures
| Measure |
OARSCM
n=21 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
n=20 Participants
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Percent Outpatient Intakes Completed - Phase 2 RCT
Yes
|
5 Participants
|
4 Participants
|
|
Percent Outpatient Intakes Completed - Phase 2 RCT
No
|
16 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: 1 month from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost to follow-up and assigned the worse possible outcome (i.e., yes, participant used opioids in past 30 days). Two OARSCM participants, one of which terminated the interview before completion, and zero TAU with MyMAT participants did the 1-month follow-up interview.
Proportion of participants with sustained abstinence (composite of biochemical \& self-report data) from opioids
Outcome measures
| Measure |
OARSCM
n=2 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Sustained Abstinence - Phase 2 RCT (Month 1)
No
|
0 Participants
|
0 Participants
|
|
Sustained Abstinence - Phase 2 RCT (Month 1)
Yes
|
2 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 3 months from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost follow-up and assigned the worse possible outcome (i.e., yes, participant used opioids in past 30 days). One OARSCM participant and zero TAU with MyMAT participants did the 3-month follow-up interview.
Proportion of participants with sustained abstinence (composite of biochemical \& self-report data) from opioids
Outcome measures
| Measure |
OARSCM
n=1 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Sustained Abstinence - Phase 2 RCT (Month 3)
Yes
|
1 Participants
|
0 Participants
|
|
Sustained Abstinence - Phase 2 RCT (Month 3)
No
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 6 months from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost follow-up and assigned the worse possible outcome (i.e., yes, participant used opioids in past 30 days). Zero participants from both arms did the 6-month follow-up interview.
Proportion of participants with sustained abstinence (composite of biochemical \& self-report data) from opioids
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 month from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost to follow-up and assigned the worse possible outcome (i.e., daily opioid use for past 30 days). Two OARSCM participants, one of which terminated the interview before completion, and zero TAU with MyMAT participants did the 1-month follow-up interview.
Longest duration of consecutive days of abstinence (composite of biochemical \& self-report data)
Outcome measures
| Measure |
OARSCM
n=2 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Longest Duration of Abstinence - Phase 2 RCT (Month 1)
|
0 Days
Standard Deviation 0
|
—
|
SECONDARY outcome
Timeframe: 3 months from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost to follow-up and assigned the worse possible outcome (i.e., daily opioid use for past 30 days). One OARSCM participant and zero TAU with MyMAT participants did the 3-month follow-up interview.
Longest duration of consecutive days of abstinence (composite of biochemical \& self-report data)
Outcome measures
| Measure |
OARSCM
n=1 Participants
OARSCM (n = 21) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
OARSCM Software Application: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
|
TAU With MyMAT
TAU (n = 20) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
MyMAT Software Application: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
|
|---|---|---|
|
Longest Duration of Abstinence - Phase 2 RCT (Month 3)
|
0.86 Days
Standard Deviation 3.93
|
—
|
SECONDARY outcome
Timeframe: 6 months from participant's enrollmentPopulation: Participants who did not answer the follow-up call were considered lost to follow-up and assigned the worse possible outcome (i.e., daily opioid use for past 30 days). Zero participants from both arms did the 6-month follow-up interview.
Longest duration of consecutive days of abstinence (composite of biochemical \& self-report data)
Outcome measures
Outcome data not reported
Adverse Events
OARSCM
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
TAU With MyMAT
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place